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Abstract
Background: Chlorpromazine (CPZ) remains one of the most common drugs used for people
with schizophrenia worldwide, and a benchmark against which other treatments can be evaluated.
Quantitative reviews are rare; this one evaluates the effects of chlorpromazine in the treatment of
schizophrenia in comparison with placebo.
Methods: We sought all relevant randomised controlled trials (RCT) comparing chlorpromazine
to placebo by electronic and reference searching, and by contacting trial authors and the
pharmaceutical industry. Data were extracted from selected trials and, where possible, synthesised
and random effects relative risk (RR), the number needed to treat (NNT) and their 95% confidence
intervals (CI) calculated.
Results: Fifty RCTs from 1955–2000 were included with 5276 people randomised to CPZ or
placebo. They constitute 2008 person-years spent in trials. Meta-analysis of these trials showed that
chlorpromazine promotes a global improvement (n = 1121, 13 RCTs, RR 0.76 CI 0.7 to 0.9, NNT
7 CI 5 to 10), although a considerable placebo response is also seen. People allocated to
chlorpromazine tended not to leave trials early in both the short (n = 945, 16 RCTs, RR 0.74 CI
0.5 to 1.1) and medium term (n = 1861, 25 RCTs, RR 0.79 CI 0.6 to 1.1). There were, however,
many adverse effects. Chlorpromazine is sedating (n = 1242, 18 RCTs, RR 2.3 CI 1.7 to 3.1, NNH
6 CI 5 to 8), increases a person's chances of experiencing acute movement disorders, Parkinsonism
and causes low blood pressure with dizziness and dry mouth.
Conclusion: It is understandable why the World Health Organization (WHO) have endorsed and
included chlorpromazine in their list of essential drugs for use in schizophrenia. Low- and middle-
income countries may have more complete evidence upon which to base their practice compared
with richer nations using recent innovations.
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Chlorpromazine is in the World Health Organization
(WHO) list of essential drugs [1]. It is estimated that 24
million people currently suffer from schizophrenia [2],
the majority of whom live in low or middle-income coun-
tries. Until recently, it would have been common practice
for anyone with schizophrenia to have been treated with
chlorpromazine at some point [3,4]. Despite well-docu-
mented adverse effects, and the advent of a new genera-
tion of antipsychotic drugs, chlorpromazine remains one
of the most commonly used and inexpensive treatments
for people with schizophrenia [5]. In Africa, chlorpro-
mazine was widely used [6], although we have failed to
identify any more recent surveys. In India chlorpromazine
is commonly prescribed, and in South East Asia the older
generation of antipsychotics are used to treat the majority
of people with schizophrenia [7]. In 2003, in the UK,
chlorpromazine was the most frequently prescribed of the
first generation 'typical' antipsychotic drugs, where, at that
time, the 'typical' group of antipsychotics accounted for
44% of all anti-psychotic prescriptions [8].
As well as its almost universal use in clinical practice, chlo-
rpromazine is a benchmark by which other treatments are
evaluated [9]. There are many qualitative reviews of chlo-
rpromazine but few attempts have been made to quantify
data from randomised controlled trials (RCTs) [10,9,11].
An up-to-date quantitative review of the effects of this old,
highly prevalent treatment is long overdue. 50 years after
its formulation, the evidence should be more complete
than when the drug was under patent.
Methods
Inclusion criteria
The inclusion criteria were defined and disseminated for
peer review within a Cochrane protocol first published
1998 [12]. Articles were included if they reported RCTs
where the participants had schizophrenia or non-affective
serious/chronic mental illness, and where the interven-
tions included chlorpromazine (any dose or mode of
administration) versus placebo or no treatment.
Identification of relevant trials
We identified relevant randomised trials by searching the
Cochrane Schizophrenia Group's register of trials (June
2002), with a phrase designed to identify the many ways
of naming chlorpromazine [see Additional file 1]. Cita-
tions in all identified articles were inspected for further tri-
als. Rhône-Poulenc Rorer (the original distributors of
chlorpromazine) was contacted to request access to
archive material, and Dr RA Pargiter (Hobart, Tasmania)
donated a large series of May and Baker chlorpromazine
reports from 1955 to 1973.
Data extraction and study appraisal
All electronic records identified were independently
inspected by BT, CA and JR. The reliability of selection
processes and data extraction was checked using a 10%
random sample. Full reports of studies of agreed relevance
were obtained, quality rated [13], and data relating to
methods, participants, interventions and outcomes,
extracted. Any disagreement was discussed and decisions
documented. If there were outstanding issues, the authors
of the studies were contacted where possible to help
resolve problems.
Statistical methods
Dichotomous and continuous data were not used if over
half of those randomised did not contribute to the out-
come due to early attrition from the study or non-compli-
ance. Dichotomous data were combined using a random
effects Relative Risk (RR) [14]. Numbers needed to treat/
harm (NNT/H) [10] were also calculated, and χ2 tests for
heterogeneity were performed. Where <50% of people
were lost to follow-up at the end of a trial, 'worst case'
intention-to-treat analyses were undertaken by assuming
that those who had left a trial early had had a poor out-
come. The sensitivity of the final results to this assump-
tion was tested. Continuous data were excluded if derived
from scales of unknown validity and if totals or measures
of variance were not reported. Summation was not
attempted where continuous data were too skewed [15].
All estimates of effect are presented with their 95% confi-
dence intervals (CI).
Results
Electronic searches identified over 1000 records, most of
which were ineligible. Full copies of 351 citations were
obtained for detailed scrutiny, including a further 50
papers identified from citations. Of these, 302 papers
were excluded and 99 reports of the 50 RCTs included
(Table 1). Studies were mainly excluded due to lack of
random allocation (68%). However, 43 randomised trials
(30%) reported irrelevant outcomes, such as serum levels
of chlorpromazine breakdown products, or presented
data in such a way as to make the outcomes unintelligible
or impossible to use.
Study quality
All 50 included studies reported the use of random alloca-
tion; only 4 were explicit about the process used. Two
used the toss of a coin [16,17], and 2 used random
number tables [18,19]. Citations to all included and
excluded studies are available in the full Cochrane Review
[12], otherwise the names and dates cited in this text relate
to Table 1. A further 2 trials [20,21] described some form
of allocation concealment (sealed envelopes in both
cases). The other 44 studies gave little assurance that bias
was minimised during the allocation procedure and thisPage 2 of 7
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METHODS PARTICIPANTS INTERVENTIONS
INCLUDED STUDIES 
(date of publication)
Randomised Double-
blind
Three+ 
arm study
Duration 
(weeks)
Only 
Schizophrenia
History Total number 
of participants
Age 
(years)
Sex CPZ dose 
(mg/day)
Number 
allocated CPZ
Number 
allocated 
placebo
Leaving 
the study 
early
1955 Hall ● ● 9 ● C 175 20–59 M+F 750 max 87 88 ●
Vaughan ● ● U/K C 48 M = 43 F 75–450 24 24
1956 Shepherd ● U/K ● 6 ● C 24 27–52 F 300 8 8 ●
1958 Abrams ● 4 ● C 40 20–55 F 200–600 20 20 ●
Grygier ● U/K 24 ● C 30 m = 50 F 150 15 15
Hine ● ● 20 ● C 22 30–50 F 750 max 11 11 ●
Simon ● ● 4 U/K 80 m = 31 U/K 200–1200 20 0 ●
1959 Baker ● ● ● 5 C 25 33–79 F 150–300 7 7 ●
Flemming ● ● ● 26 ● C 63 m = 58 F 75–300 21 21 ●
Walsh ● U/K ● 8 ● C 66 27–50 F 75–300 22 22
1960 Englhardt ● ● ● 78 ● U/K 173 18–40 U/K 50–800 62 56 ●
Hamilton ● ● ● 8 ● C 54 m = 38 M 300 18 18 ●
Payne ● ● ● 6 ● C 21 23–73 M 25–100 7 7
Somerville ● ● ● 6 C+A 60 24–58 F 200–800 15 30 ●
1961 Clark ● ● ● 24 ● C 60 26–52 F 200–800 20 20
Lorr ● ● ● 12 A 308 <50 M 50–100 63 61 ●
Kurland ● ● ● 6 A 277 18–61 M+F 300 33 72 ●
Schiele ● ● ● 16 ● C 80 m = 80 M 200–1000 20 20 ●
Smith ● ● ● 14 ● C 30 m = 42 M+F 150–600 13 15
1963 Bishop ● ● ● 10 ● C 30 U/N M+F 800 10 10 ●
Fink ● U/K ● 6 S 311 m = 31 M+F 1200 51 44 ●
1964 NIMH ● ● ● 6 ● A 463 16–45 M+F 200–1600 112 125 ●
1966 Reardon ● ● ● 4 ● A 34 U/K M+F 300–600 11 12 ●
Saretsky ● ● 12 ● A 40 <55 M 400 20 20 ●
1967 Clark ● ● 10 ● C 72 25–55 F 678 m 51 21 ●
Letemendia ● ● 39 C 28 <65 M 300 14 14 ●
1968 Clark a ● ● ● 14 ● C 72 20–60 F 1000 max 18 36 ●
Clark b ● ● ● 16 ● C 69 20–60 F 1000 max 23 23 ●
Cohen ● ● ● 60 ● C 126 18–42 M+F 180 42 42 ●
Prien ● ● ● 24 ● C 838 19–55 M+F 2000 208 212
300 208
1969 Tetreault ● ● ● 12 ● C 45 m = 50 F 300–600 15 15 ●
1970 Clark a ● ● ● 12 ● C 44 22–55 M+F 200–1000 15 14 ●
Clark b ● ● 24 ● C 71 21–60 F 150–600 54 18 ●
1971 Clark ● ● ● 4 ● C 86 21–45 M+F 200–1000 23 21 ●
1972 Clark ● ● ● 12 ● C 55 21–60 M+F 1000 19 18 ●
Serafetinedes ● ● ● 12 ● C 57 21–61 M+F 1000 max 14 13 ●
1973 Hogarty ● ● 156 ● S 374 18–53 M+F 270 m 192 182 ●
Klein ● ● 6 ● 88 17–61 M+F 300–1200 46 42 ●
1974 Reschke ● ● ● 0.1 ● A 50 19–57 M+F 25 im 10 11 ●
1975 Ban ● ● ● 12 ● C+A 30 17–46 M+F 200–800 10 10 ●
Hamill ● 0.7 ● A 44 18–55 M+F 306–475 22 22 ●
1977 Clark ● ● ● 12 ● C 27 23–61 M+F 1000 9 9 ●
Spohn ● ● 6+ ● U/K 40 18–55 M+F 200 min 20 20
1978 Rappaport ● U/K ● A 127 16–40 M 300–900 53 74 ●
1981 Peet ● ● ● 12 ● U/K 53 m = 51 M+F 400 max 16 18 ●
1982 Nishikawa ● ● ● 156 ● S 55 m = 33 M+F 75 10 10
1986 Zuoze ● ● 4 ● C 60 m = 36 U/K 450 m 20 20
1990 Chouinard ● ● ● 4 ● A 62 19–62 M+F 300–1200 21 21 ●
1991 Borison ● ● ● 4 ● A 30 22–58 M 400–1600 9 10
2000 Cooper ● ● ● 8 ● C 159 18–42 M+F 600 53 53 ●
Key: ● = Yes; U/K = Unknown; C = Chronic; A = Acute; M = Male; F = Female; m = Mean; im = Intramuscular injection.
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rpromazine [22]. Twenty-eight (56%) of the trials ade-
quately described their attempts to be double-blind, with
two [20] and [23] reporting how successful these attempts
were. Two studies [18] and [24] gave no indication that
blinding had been attempted. Other trials indicated that
an attempt at blinding had been made, but they gave no
description of how this had been done. The description of
participants who left studies early was poor; 12 of the 50
included studies providing no details of treatment with-
drawals. Presentation of data was also poor. Trials fre-
quently presented both dichotomous and continuous
data in graphs, or reported inexact statistical measures of
probability, for example p > 0.05. This often made it
impossible to extract raw data for synthesis. Continuous
scale data were frequently collected in the trials, but were
often poorly reported; 30/50 trials did not report standard
deviations and 9/42 did not present any data from the
scales they had used.
Study designs
The studies were mostly either 6 or 12 weeks long, but the
range was large (24 h to 3 years). The great majority of par-
ticipants in nearly all of the trials were diagnosed as suf-
fering from schizophrenia. These studies reported on
>5276 people, 3318 of whom were allocated to chlorpro-
mazine-placebo comparison. Eleven of the 50 trials
described the diagnostic criteria used, or the symptoms
required for people to be included. Otherwise entry to
most of the included studies was based on a pragmatic
diagnosis of schizophrenia. The trials ranged in size from
21 [25] to 838 participants [26]. Most people were hospi-
talised at the time of the study. The lowest dose of chlo-
rpromazine tested was 25 mg/day [27] and the highest
2000 mg/day [26]. One trial [28] included both a placebo
and a no-drug group, which we combined. Another study
included both a placebo group and a "routine conven-
tional hospital treatment" group [26]. Data from the latter
were not used in this review, as people in this group will
probably have been given antipsychotic drugs.
Outcomes
Table 2 presents the main results of this review. These
intention-to-treat data are derived by synthesising homo-
geneous trial findings. The results remain essentially
unchanged when we only used data from participants
who completed the studies. The data show no clear pat-
tern indicative of publication bias when sorted by study
size and effect [29].
Data on global improvement (a dichotomised impression
of change), in the period up to 6 months favours chlorpro-
mazine (n = 1121, 13 RCTs, RR No global improvement
0.76 CI 0.7 to 0.9) but is moderately heterogeneous (I2 =
52.8%). Global severity of illness at study end (a dichot-
omised impression of clinical state) also favours chlorpro-
mazine (n = 778, 5 RCTs, RR severely ill 0.67 CI 0.5 to 0.8,
NNT 4 CI 3 to 10; Figure 1). Very few studies present usa-
ble data directly relating to end point mental state. The
continuous data that are available (Brief Psychiatric Rat-
ing Scale [30] are equivocal (n = 49, 2 RCTs, RR -4.82 CI -
8.5 to 1.2). Most information on behaviour relates to a
dichotomous outcome of 'behaviour deteriorated/dis-
turbed/uncooperative' (n = 1127, 10 RCTs, RR 0.53 CI 0.3
to 0.9) but these data are heterogeneous (χ2 73, df 9, p <
0.00001).
Chlorpromazine has many adverse effects (Table 3). It is a
sedative (n = 1242, 18 RCTs, RR 2.3 CI 1.7 to 3.1, NNH 6
CI 5 to 8) that may cause weight gain (n = 165, 5 RCTs, RR
4.44 CI 2.1 to 9.3, NNH 3 CI 2 to 5). Extrapyramidal
symptoms are common and include acute dystonias (n =
780, 4 RCTs, RR 3.1 CI 1.3 to 7.7, NNH 24 CI 15–57) and
Parkinsonism (n = 1265, 12 RCTs, RR 2.6 CI 1.2 to 5.4,
NNH 10 CI 8 to 16). Data on chronic movement disor-
ders such as tardive dyskinesia, however, are not available
from this review as this requires longer follow-up than
was attempted for nearly all the trials. Occurrence of aka-
thisia is similar in the chlorpromazine and placebo
groups. For every 7 people given chlorpromazine, one will
experience some form of photosensitive reaction (n = 799,
6 RCTs, RR 5.19 CI 3 to 10, NNH 7 CI 6 to 10); hypoten-
sion and dizziness are common (n = 1232, 15 RCTs, RR
Table 2: Results relating to clinical change and study attrition.
Months Number of trials Chlorpromazine Placebo RR (95% CI) Test for heterogeneity
events/total participants
Relapse 6–24 3 108/202 159/192 0.65 (0.5–9.0) Chi2 7.83, df 2, p = 0.02 I2 = 74.5%*
No global improvement 2–6 13 470/654 406/467 0.76 (0.7–0.9) Chi2 25.4, df 12, p = 0.01 I2 = 52.8%
Leaving the study early 6–24 2 38/254 33/238 1.09 (0.7–1.6) Chi2 0.47, df 1, p = 0.49 I2 = 0%
* no clear cause of heterogeneity found on close re-inspection of trialsPage 4 of 7
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BMC Medicine 2005, 3:15 http://www.biomedcentral.com/1741-7015/3/151.9 CI 1.4 to 27, NNH 12 CI 8 to 22); and dry mouth is
considerably increased (n = 756, 5 RCTs, RR 4.00 CI 1.6
to 10, NNH 18 CI 13 to 37). Eye opacities, as identified by
slit-lamp examination within one large trial using high
dose chlorpromazine 2 gms/day [26], were increased
within the drug group (n = 657, RR 3.09 CI 1.9 to 5.1,
NNH 7 CI 5 to 10). There were no significant differences
between people given placebo and those allocated chlo-
rpromazine in the frequency of complaints of constipa-
tion, urinary retention and blurred vision.
There were no reports of deaths occurring during any of
the studies. Any data relating to violent incidents, hospital
discharge or admissions, presence of delusions or halluci-
nations were either absent or impossible to use. Not one
of the studies, even in recent years, reported levels of sat-
isfaction and quality of life, nor could we identify any
direct economic evaluation of chlorpromazine.
Discussion
These 50 studies amounted to a total of >2000 person-
years of exposure to chlorpromazine or placebo. For peo-
ple with this serious mental illness, and certainly in
situations were resources are limited, chlorpromazine
remains a first line treatment. The medium term data on
improvement suggest that about 7 people have to be
treated for one to have what the trialists would describe as
'global improvement' (n = 1121, 13 RCTs, RR 0.76 CI 0.7
to 0.9, NNT 7 CI 5 to 10). This outcome relates to a simple
dichotomised impression of a person's mental state,
behaviour and functioning. Given the limited quality of
reporting and the fact that we may be only able to pool
data from a subset of the included trials, even this finding
may be an over estimate of the positive and an underesti-
mate of the negative effects of giving chlorpromazine.
The increased likelihood that people given chlorpro-
mazine continued in their trial may be heartening. It
Chlorpromazine versus placebo – global outcomesFigu e 1
Chlorpromazine versus placebo – global outcomes.Page 5 of 7
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toms of schizophrenia that led to an increased compli-
ance with medication, despite common and unpleasant
adverse effects such as sedation and hypotension. Doctors
and nurses may, at times of acute disturbance, welcome
this sedative effect but people with schizophrenia may
not.
Despite limitations, this review provides quantitative evi-
dence to confirm many of the impressions held by clini-
cians and recipients of care about the effects of
chlorpromazine. Chlorpromazine is a sedating drug,
prone to cause movement problems. Reliable evidence
about its short-term effects is surprisingly weak, but infor-
mation from studies that are >6 months does suggest that
chlorpromazine facilitates a global improvement and may
decrease the likelihood of behaving in a disturbed man-
ner, at least within the confines of hospital.
Conclusion
Chlorpromazine represents a low-cost choice for clini-
cians world-wide and merits its position as a benchmark
treatment for psychotic symptoms. Until large, high qual-
ity, clinically relevant trials show equally inexpensive
treatments to be both more effective and safe, chlorpro-
mazine is likely to continue to be one of the most widely
used treatments for the millions of people who suffer with
schizophrenia.
Although the NNTs may seem high, and the NNHs low,
these estimates are likely to be more realistic than those
for new drugs, for which all evidence has not been made
available. As time passes, studies not seen in the early
years of marketing tend to become apparent. These stud-
ies may be systematically different from those initially
used to sell the drug. As a result, clinical practice of low
and middle-income countries, often having to use older
generations of drug, may, nevertheless, have more chance
of being based on all evidence than that of high income
nations. The latter are prone to purchase new expensive
innovations the evidence for which is treated with sensi-
tivity by researchers, marketers, and licensing agencies
mindful of pecuniary influences.
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Search strategy for identification of studies. The Schizophrenia Group's 
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on the Cochrane Library.
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